SG11201407209YA - Methods for preventing biofilm formation - Google Patents

Methods for preventing biofilm formation

Info

Publication number
SG11201407209YA
SG11201407209YA SG11201407209YA SG11201407209YA SG11201407209YA SG 11201407209Y A SG11201407209Y A SG 11201407209YA SG 11201407209Y A SG11201407209Y A SG 11201407209YA SG 11201407209Y A SG11201407209Y A SG 11201407209YA SG 11201407209Y A SG11201407209Y A SG 11201407209YA
Authority
SG
Singapore
Prior art keywords
international
methods
sanofi
espagne
tsu
Prior art date
Application number
SG11201407209YA
Inventor
Astrid Rey
Sylvie Lefort
Laurent Fraisse
Jeremy Yethon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201407209YA publication Critical patent/SG11201407209YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/169657 A1 (51) International Patent Classification: C07K16/12 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/039724 6 May 2013 (06.05.2013) English English (30) Priority Data: 61/643,650 7 May 2012 (07.05.2012) US (71) Applicant: SANOFI [FR/FR]; 54 Rue La Boetie, F-75008 Paris (FR). (72) Inventor; and (71) Applicant : YETHON, Jeremy [US/US]; 38 Sidney Street, Cambridge, MA 02139 (US). (72) Inventors: REY, Astrid; TSU ID SANOFI R&D, 195 Route D'espagne, Bpl3669, F-31036 Toulouse Cedex 1 (FR). LEFORT, Sylvie; TSU ID SANOFI R&D, 195 Route D'espagne, BP 13669, F-31036 Toulouse Cedex 1 (FR). FRAISSE, Laurent; TSU ID SANOFI R&D, 195 Route D'espagne, Bpl3669, F-31036 Toulouse Cedex 1 (FR). (74) Agents: VELEMA, James, H. et al.; Lathrop & Gage LLP, 28 State Street, Suite 0700, Boston, MA 02109-1701 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) o\ i-H en i-H o CJ (54) Title: METHODS FOR PREVENTING BIOFILM FORMATION (57) Abstract: Provided are methods for the treatment or prevention of microbial infections (e.g., nocosomial infection) in which the underlying pathology involves PNAG-containing microbial a bio film. The methods the invention generally involve administering to the subject an effective amount of an antibody that specifically binds PNAG and disrupt to or inhibit formation of PNAG-containing microbial bio films. Such methods are particularly useful for the treatment of nosocomial staphylococcus (e.g., S.epidermidis and S. aureus) infections.
SG11201407209YA 2012-05-07 2013-05-06 Methods for preventing biofilm formation SG11201407209YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
PCT/US2013/039724 WO2013169657A1 (en) 2012-05-07 2013-05-06 Methods for preventing biofilm formation

Publications (1)

Publication Number Publication Date
SG11201407209YA true SG11201407209YA (en) 2014-12-30

Family

ID=48464117

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407209YA SG11201407209YA (en) 2012-05-07 2013-05-06 Methods for preventing biofilm formation

Country Status (8)

Country Link
EP (1) EP2847216A1 (en)
CN (1) CN104662042A (en)
AU (1) AU2013259786A1 (en)
CA (1) CA2872856A1 (en)
HK (1) HK1208475A1 (en)
MX (1) MX2014013637A (en)
SG (1) SG11201407209YA (en)
WO (1) WO2013169657A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022009924A2 (en) * 2019-11-22 2022-08-09 Alopexx Inc METHODS TO PROVIDE CONTINUOUS THERAPY AGAINST PNAG UNDERSTANDING MICROBES

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (en) 1990-03-20 1997-10-15 Univ Columbia CHIMERIC ANTIBODIES WITH RECEPTOR-BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION
WO1992008495A1 (en) 1990-11-09 1992-05-29 Abbott Biotech, Inc. Cytokine immunoconjugates
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP2001506967A (en) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー Methods for suppressing immunoglobulin-induced toxicity as a result of the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CN1202128C (en) 1998-12-08 2005-05-18 拜奥威神有限公司 Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
BRPI0314814C1 (en) 2002-09-27 2021-07-27 Xencor Inc antibody comprising an fc variant
PT1562972E (en) 2002-10-15 2010-11-10 Facet Biotech Corp Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007503206A (en) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド Improved antibody with altered effector function and method for producing the antibody
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2154157A3 (en) 2004-01-12 2010-04-28 Applied Molecular Evolution Inc. FC region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
KR100863776B1 (en) 2004-07-15 2008-10-16 젠코어 인코포레이티드 OPTIMIZED Fc VARIANTS
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION

Also Published As

Publication number Publication date
HK1208475A1 (en) 2016-03-04
CA2872856A1 (en) 2013-11-14
AU2013259786A1 (en) 2014-11-20
EP2847216A1 (en) 2015-03-18
MX2014013637A (en) 2015-02-05
CN104662042A (en) 2015-05-27
WO2013169657A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809082WA (en) Nlrp3 modulators
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408261UA (en) Syringe
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407981RA (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
SG11201803933PA (en) Optical metrology of lithographic processes using asymmetric sub-resolution features to enhance measurement
SG11201407214RA (en) Position indicator for valves
SG11201407890VA (en) Tetrahydropyrazolopyrimidine compounds
SG11201407372UA (en) Nampt inhibitors
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201407537YA (en) Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
SG11201408123SA (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
SG11201408174UA (en) Antibody formulation
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201408232RA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors